Pfizer Inc. is considering the sale of a group of treatments in cardiology, urology and primary care to raise cash and streamline its portfolio, according to a Bloomberg article.
The drugs are said to have sales of more than $700 million, and sellers could pay more than $2 billion for the portfolio, says sources familiar with the matter. Pfizer is reportedly working with financial advisers at JPMorgan Chase & Co., which is at a preliminary stage, the people said.
Read the Bloomberg story